High Dose Granulocyte Transfusions for the Treatment of Infection in Neutropenia

The RING Study (Resolving Infection in Neutropenia with Granulocytes)

Protocol TMH-04, Version 6.0 – March 15, 2011

Study Sponsor: National Heart, Lung, and Blood Institute

Project Officer: Traci Mondoro, PhD

Conducted by the Transfusion Medicine/Hemostasis Clinical Trials Network

CONCEPT SYNOPSIS AND STUDY SCHEMA

Indications Studied:
The study will evaluate patients with severe neutropenia due to marrow failure caused by underlying disease or therapy, and have a proven, probable, or presumptive infection.

Herein, "subjects" refers to neutropenic patients as described above. "Donors" refers to community or family donors of G-CSF/dexamethasone-mobilized granulocytes.

Primary Objective
To evaluate whether subjects treated for neutropenia who receive G-CSF/dexamethasone-mobilized granulocyte transfusions in addition to antimicrobial therapy will be more likely to survive to 42 days and achieve microbial response, compared to subjects who receive antimicrobial therapy alone.

Secondary Objectives
1) To evaluate safety in each of the randomized treatment groups.
2) To determine the efficacy of G-CSF/dexamethasone-mobilized granulocyte transfusions.
3) To evaluate 3-month survival of subjects who received G-CSF/dexamethasone-mobilized granulocyte transfusions and antimicrobial therapy compared to subjects who received antimicrobial therapy alone.

Population
1) Subjects who have severe neutropenia due to marrow failure caused by underlying disease or therapy
2) Subjects must have a fungemia, bacteremia, proven or presumptive invasive tissue bacterial infection, or proven/probable/presumptive invasive tissue fungal infection confirmed by culture, histopathologic, or radiologic criteria.
3) Subjects must meet the eligibility criteria discussed in section 3.1 and 3.2.

Study Design
This is a two arm, unblinded, Phase III, randomized clinical trial.

After evaluation for eligibility, subjects will be randomized to receive either G-CSF/ dexamethasone-mobilized granulocyte transfusion in addition to antimicrobial therapy or antimicrobial therapy alone. Subjects in the granulocyte arm will receive daily granulocyte transfusions for up to 42 days. Subjects in both arms will receive antimicrobial therapy (see Appendix A, Section III). Subjects will receive study treatments and testing for 42 days after randomization and be followed for a total of 3 months to evaluate survival.

STUDY OVERVIEW - SUBJECTS

	Subject with neutropenia and active infection
	↓
Consent	Subject consents to participation in study
	↓
Screening Phase	Subject is evaluated for eligibility criteria
	↓
	If eligible, subject will be randomized to receive granulocytes plus antimicrobial therapy or antimicrobial therapy alone
	↓
Treatment Phase	Subject receives G-CSF/dexamethasone-mobilized granulocyte transfusions in addition to antimicrobial therapy or antimicrobial therapy alone
	↓
Follow-Up Phase	Subject evaluated 42 days after randomization to determine survival and microbial response
	↓
	Subject is followed to evaluate 3-month survival

STUDY OVERVIEW - DONORS

Screening Phase

> **Obtain informed consent**

↓

> **Evaluate donor for eligibility as dictated by SOP at blood collection facility**

↓

Treatment Phase

> **If eligible, donor is given G-CSF/dexamethasone treatment 8 to 16 hours prior to leukapheresis**

↓

> **Leukapheresis**

↓

Follow-Up Phase

> **Donor provided with instructions regarding safety follow-up as dictated by blood collection facility**

Table of Contents

1   BACKGROUND AND SIGNIFICANCE

Infections in neutropenic subjects continue to cause substantial morbidity and mortality in the setting of aggressive chemotherapy and hematopoietic stem cell (HSC) transplantation. In particular, fungal infections are becoming an increasingly important cause of death in neutropenic cancer and HSC transplant subjects [1-3]. For example, among marrow transplant recipients treated at Fred Hutchinson Cancer Research Center (FHCRC) using fluconazole as antifungal prophylaxis and ceftazidime as antibacterial prophylaxis during 1992-1996, only 40% (23 of 58 subjects) who developed fungemia during neutropenia had clearance of the fungemia within 10 days of the first positive blood culture and survived to 4 weeks. Similarly, < 30% of subjects who developed invasive mold infections during neutropenia who were transplanted during 1992-1996 were alive at 12 weeks after the onset of infection.

The strongest predictor of progression and recovery from invasive infection in the cancer/stem cell transplant setting is the recovery of adequate neutrophils [4]. Therefore, any method that provides adequate numbers of functional neutrophils to infected subjects during the neutropenic period should be of benefit. Transfusion of granulocyte concentrates obtained without growth factor stimulation was shown to be of benefit for the treatment of gram-negative bacteremia outside the marrow transplant setting, with survival increasing from 36% for the control group to 75% for the 27 subjects who were transfused in one study [5]. Other trials have also shown a benefit [6, 7] or a partial benefit [8, 9] from transfusions. In spite of these results, however, granulocyte transfusion therapy fell out of favor, primarily because of unimpressive clinical results, most likely due to the fact that only relatively small doses of granulocytes could be provided. The current renewed interest in this form of therapy springs from the ability to deliver much greater numbers of cells by stimulating granulocyte donors with recombinant granulocyte colony-stimulating factor (G-CSF).

The use of G-CSF to mobilize granulocytes from donors for transfusion to severely neutropenic subjects was first reported in 1993 [10, 11]. The study of Bensinger et al [10] followed a series of careful investigations of the effects of G-CSF on neutrophil kinetics and function in normal subjects [11-14]. In the Bensinger study, treatment of donors with G-CSF permitted collection of 2 to 6 times as many cells as were collected previously from donors treated with corticosteroids. Perhaps more importantly, this study demonstrated that neutrophils collected with G-CSF remained in the circulation much longer than had ever been noted before. The mean neutrophil count at 24 hours post-transfusion was nearly 1×10^9 cells/L [10].

In a further effort to optimize the collection of granulocytes, Liles et al compared G-CSF (300 or 600 μg) with or without dexamethasone (8 mg P.O.) versus dexamethasone alone, with measurement of the CBC at 0, 6, 12, and 24 hours [15]. These studies showed that the blood neutrophil count of normal subjects could be elevated as much as ten-fold at 12 hours after G-CSF (600 μg) and dexamethasone (8 mg), and suggested that the optimum time for leukapheresis was 12 hours after this combination. Dexamethasone significantly increased the maximal ANC induced by either low dose (300 μg) or high-dose (600 μg) G-CSF [15]. In a second study, the response to 450 μg G-CSF plus dexamethasone (8 mg) was equivalent to 600 μg G-CSF plus dexamethasone (8mg) [16]. Based on these results, the kinetics and function of neutrophils collected by leukapheresis 12 hours after single doses of G-CSF (600 μg) and dexamethasone (8 mg) were determined [17]. This study showed that approximately 8.0×10^{10} neutrophils could now be routinely collected, and the recovered neutrophils circulated with a significantly prolonged half-life when re-infused into donors. The functional properties for these cells were normal or near normal.

A phase I/II trial of G-CSF and dexamethasone-mobilized granulocyte transfusions was conducted for subjects with documented fungal and/or bacterial infections [18]. Data for the first 165 transfusions (1 to 17 transfusions per subject, mean 8.6 transfusions per subject) showed that transfusion of approximately 8.0×10^{10} neutrophils increased blood neutrophil counts to normal (i.e., greater than 1.5×10^9/L) in almost all subjects. Thereafter, continued transfusion maintained counts in the normal range in recipients who were previously severely neutropenic. The study also demonstrated that these cells had the capacity to migrate to the oral cavity (demonstrated with oral washes with neutrophil counting). Clearance of fungemia was also documented. Careful monitoring of these subjects showed that hypoxia (as reflected by regular monitoring of oxygen saturation), fever, chills, and other adverse events attributable to the transfusions occurred very infrequently. Most importantly, this trial showed that it was feasible to use community donors as a source for granulocytes for supportive care in this setting. Infection resolved in 8/11 subjects with invasive bacterial infections or candidemia; none of the eight subjects with invasive mold infection, however, survived 30 days to document clearance of infection. Of note, this trial was conducted prior to the availability of antifungal agents that are more effective and less toxic than conventional amphotericin B, including the third generation triazole voriconazole [19]. It is possible that the administration of more effective therapy would allow the incremental benefit of granulocyte therapy to be demonstrated, but this hypothesis remains to be proven.

Figure 1: Percentage of progressive or fatal infection at day 30 after diagnosis, by infection type

Key
White bars = unrelated granulocyte donors
Checked bars = related granulocyte donors
Striped bars = control subjects
All comparisons NS with exception of bacterial infections (p=0.04). From Hubel et al [20].

More recent studies of related and unrelated granulocyte transfusions have shown that recipients of unrelated granulocytes have a shorter time from diagnosis to first transfusion when compared to recipients of granulocytes from relatives, which might theoretically lead to improved outcomes [20]. Although some subjects with mold infection who received unrelated or related granulocytes did survive in this study, their survival was no greater when compared with a matched cohort that received antifungal therapy alone (Figure 1). These negative results must be interpreted with caution. This study was not a prospective randomized study, the "controls" were partly historical, and the subjects selected to receive granulocyte transfusions are likely to have had more severe illness. Regardless, these data do not provide clear evidence that granulocyte transfusions are clinically effective. Rather, the data indicate that effectiveness must be proven in a trial where severity of illness is controlled via the randomization process.

No recipient of granulocyte transfusions in the study of Price et al developed anti-neutrophil antibodies [18]. During the course of the study, a positive lymphocytotoxic crossmatch with the neutrophil donor was detected in 8 of the 19 (42%) subjects. The presence of leukocyte antibodies had no effect on the post-transfusion neutrophil increment or the buccal neutrophil responses, nor did they affect the incidence of transfusion-related side effects such as chills, fever or hypoxemia [18]. Adkins and colleagues, however, found that subjects with a positive

lymphotoxicity screening assay who received prophylactic granulocyte transfusions from related donors had delayed neutrophil engraftment, more febrile days, and greater platelet transfusion requirements [21].

Recent studies have addressed the feasibility of multicenter granulocyte transfusion trials. In a multicenter trial that was coordinated by the National Marrow Donor Program, five centers in the US successfully provided daily granulocyte transfusions obtained from predominantly unrelated community donors for 40 subjects with serious infections during neutropenia [22]. Of the 351 days that granulocytes were required by protocol, 329 transfusions were administered (94% success in administration). Survival with complete or partial responses at 4 weeks after enrollment in this contemporary series varied by infection type [9/24(38%) for invasive mold infection, 2/5 (40%) for bacteremia/candidemia, 6/10 (60%) for severe bacterial infection]. Adverse events were also frequent in this seriously ill population (median 2 AEs/subject, range 0-11), though only two serious adverse events (two cases of transfusion-associated lung injury that resolved with discontinuation of granulocyte support) were deemed related to the granulocyte therapy. These data provide further evidence that granulocyte transfusion therapy is feasible. Clinical efficacy, however, appears to vary considerably according to the population studied, again highlighting the need for prospective, randomized studies.

Several additional studies have also shown that G-CSF administration to normal donors is well tolerated and results in the collection of large numbers of apparently normally functioning granulocytes and that these cells circulate when administered to neutropenic subjects [23-26]. Apparent clinical efficacy in these uncontrolled studies has been mixed [23-25, 27].

The safety of short-term administration of G-CSF (+/- corticosteroids) to normal donors has been studied extensively; both in the setting of stimulation of granulocyte donors and for the collection of peripheral blood stem cells. Stroncek et al [28] and Anderlini et al [29] reported on the effects of five days of G-CSF administration in 142 donors. Symptoms were seen in 90-98% of donors, consisting of bone aching, headache, myalgia, fatigue, and nausea in 80%, 40-70%, 25%, 15%, and 10% of subjects, respectively. These symptoms were mild to moderate in most donors and were effectively treated with antipyretics and anti-inflammatory agents. Symptoms resolved within a few days after the last dose of G-CSF, and the donor's leukocyte count returned to normal within 7-10 days. Adverse effects seen in donors given only one dose of G-CSF are similar to those given multiple doses, but the incidence is less, the symptoms less intense, and the duration shorter. In a study of 82 community donors stimulated once with 600ug G-CSF and 8 mg dexamethasone, 41%, 30%, and 30% experienced mild to moderate bone pain, headache, and insomnia, respectively. Twenty eight percent of these donors experienced no side effects, and 98% indicated a willingness to undergo future G-CSF stimulation for leukapheresis [18]. Two studies have shown that spleen size increases in donors given G-CSF for five days and returns to normal after the drug is discontinued [30,31]. Rare side effects of G-CSF treatment of normal donors, almost always seen only after multiple doses, have included exacerbation of underlying inflammatory or immunologic disorders, cardiac events in donors with underlying coronary artery disease, crisis and even death in subjects with sickle cell disorders, and splenic rupture. Long term side effects have not been reported. The National Marrow Donor Program has in place a comprehensive long-term follow-up program for all donors given G-CSF for peripheral blood stem cell collection, to date consisting of over 3000 donors. Because of this extensive body of knowledge and the large ongoing study being conducted by the National Marrow Donor Program, it is not the intention of the proposed investigation to study the donor effects of G-CSF or dexamethasone.

Thus several investigators have shown that G-CSF (+/- corticosteroid) stimulation of normal donors is well tolerated, although side effects do exist, and results in the ability to collect large numbers of apparently functional cells. The transfusion of these large numbers of granulocytes is in general well tolerated by subjects, although serious side effects can occur, particularly pulmonary reactions. These reactions do not seem to be any more common that those seen with the administration of granulocytes obtained without donor G-CSF stimulation. The major question to be answered is whether the transfusion of large doses of granulocytes is clinically effective in eradication of infection and/or prolonging subject survival. Evidence for efficacy to date is only anecdotal or based on small uncontrolled series. Some of these series have suggested efficacy, impressing some clinicians that the therapy is useful; others have been less impressive. The current situation is thus one of clinical equipoise. It is not clear whether this rather expensive therapy would be advantageous, disadvantageous, or neutral, given that clinical efficacy is uncertain and there are known possible adverse effects for both donor and subject. The proposed Phase III randomized controlled study is designed to determine whether transfusion of granulocytes to subjects with documented bacterial or fungal infection during neutropenia is associated with significant improvement in clinical outcome.

2   OBJECTIVES

2.1   Primary Objective

The primary endpoint of this study for subjects includes survival to 42 days after randomization AND microbial response, which will depend on infection type at enrollment. The response will be defined as a negative blood cultures test at 42 days after randomization for subjects with fungemia (candidemia or fusariosis) or bacteremia, and the improvement of signs and symptoms of infectious disease (complete or partial response) at 42 days after randomization.

Achievement of the primary endpoint in neutropenic subjects who receive G-CSF/dexamethasone-mobilized granulocyte transfusions in addition to antimicrobial therapy will be determined and compared with control subjects who receive antimicrobial therapy alone. Antimicrobial therapy is broadly defined for a particular infection, but recommended antimicrobials for various infection types are listed in Appendix A. Experimental anti-microbial agents are also allowed.

2.2   Secondary Objectives

1. Safety among subjects in the two randomized treatment groups, including the occurrence of the following endpoints:
   - Alloimmunization, defined as the appearance of anti-HLA or anti-neutrophil antibodies
   - Serious granulocyte transfusion reactions, including febrile, allergic and pulmonary reactions (transfusion arm only)
   - Graft vs. host disease among recipients of allogeneic stem cell transplantation
   - Overall incidence of adverse effects
   - Incidence of discontinuation of transfusions due to toxicity or intolerance (transfusion arm only)

2. Efficacy, determined by:
   - Outcome within each infection subgroup (invasive mold, invasive bacterial, etc) according to randomization arm

- Time to resolve fever
- Time to negative test for fungal antigenemia (e.g. galactomannan antigenemia among subjects with invasive aspergillosis)
- Time to negative blood culture for subjects with positive blood culture at baseline.

3. Long-term survival. Though overall survival often primarily reflects disease status (rather than response to anti-infective therapy), we will follow all randomized subjects until 3 months after randomization for comparison of long-term survival.

2.3 Donor Objectives
1. Donor safety
2. Donor availability
3. Evaluation of granulocyte yield

3 STUDY POPULATION

3.1 Subject Inclusion Criteria
1. Subjects must have severe neutropenia (ANC < 500/mm^3) due to marrow failure caused by underlying disease or therapy.
2. Age: All ages
3. Subjects must have one of the following, as defined in Appendix A:
   - fungemia;
   - bacteremia;
   - proven or presumptive invasive tissue bacterial infection; or,
   - proven, probable or presumptive invasive fungal infection.

Once determined to be eligible for the study, subjects must be consented (if not previously consented) and randomized within 7 days. The 7-day period will start with the <u>first</u> time the patient meets the eligibility criteria as per the <u>report time</u> of the relevant test results. For presumptive invasive tissue bacterial or fungal infections, the 7-day period will start when the clinical team determines that the subject meets all eligibility criteria. RING study staff must document the date and time this decision is made in the subject's study files or medical records. Subjects should receive the first granulocyte transfusion (if in the treatment arm) as soon as possible after randomization; every effort should be made to provide the first transfusion within 48 hours after randomization.

3.2 Subject Exclusion Criteria
1. Any subject unlikely to survive five days
2. Evidence that patient will not be neutropenic for at least 5 days
3. Subjects previously enrolled in this study

3.3 Donor Inclusion Criteria
1. Donor screening. All donors will meet the standard blood donor criteria established by the participating local blood center, American Association of Blood Banks (AABB) and FDA regulations.

2. Though long-term toxicity is not expected with the frequent administration of G-CSF, dexamethasone, or red cell sedimenting agents, community donors will be restricted to a maximum of one donation every three days and no more than 8 donations per year in order to limit cumulative exposure to these agents. Family donors will be able to donate at any interval according to local blood bank criteria, with approval from a blood bank physician. Family donors will be limited to 8 donations per year.

Donors will be selected from each participating center's pool of volunteer community blood donors and/or from among the subject's friends or relatives. Infectious disease testing will be done per local blood bank policy and procedures. A product may be administered before infectious disease testing results are known per local blood bank policy. Donor and intended recipient will be red cell compatible. Donors will not be pre-selected on the basis of HLA or granulocyte type. If patient is CMV-negative, only donors who are CMV-negative will be used. CMV serology of the donor will be tested within 30 days prior to the granulocyte donation. Donations from CMV-positive donors will not be transfused to CMV-negative recipients.

3.4 Donor Exclusion Criteria
1. Personal or family history of severe sickle cell disease or variant (unless donor has tested negative). Testing for the presence of Hemoglobin S is not required.
2. Positive infectious disease test as dictated by blood collection center's SOP
3. Current uncontrolled hypertension
4. Diabetes mellitus
5. Active peptic ulcer disease
6. Pregnant or breast-feeding
7. Currently taking lithium therapy
8. History of autoimmune disease
9. History of coronary disease
10. History of deep vein thrombosis or venous thromboembolism
11. History of iritis or episcleritis.

4 TRIAL ENROLLMENT

4.1 Recruitment/Screening
Subjects will be recruited through the Transfusion Medicine/Hemostasis Clinical Trials Network and additional non-Network sites. Potentially eligible subjects will be identified by the subject's physician. Screening logs will be maintained at each site to track the enrollment status of all patients considered for participation. Each subject will be counseled regarding center-specific options for the treatment of life-threatening infections in neutropenia; these would include (but are not limited to) granulocyte transfusions and other investigational pharmacologic agents. Subjects and donors must meet the eligibility criteria described in 3.1 through 3.4.

Donors will be counseled regarding the risks and hazards of the granulocyte harvest procedure.

Consent for both donor and recipient will be obtained using forms approved by the local institutional IRB.

4.2 Stratification and Randomization

Treatment group will be allocated using randomly permuted blocks within strata [32]. Subjects will be stratified according to risk status (high risk: stem cell transplantation or relapsed leukemia vs. other), and type of infection (invasive mold infection* vs. other) in order to ensure balance for these important factors. Treatment allocation will also be balanced within each clinical center using dynamic balancing [32].

Subjects will be randomized with equal allocation to two treatment groups:
1. Antimicrobial therapy alone
2. Antimicrobial therapy plus daily G-CSF/dexamethasone-mobilized granulocyte transfusion therapy

In order to facilitate the administration of study granulocytes at the time of infection in the neutropenic period following transplantation and/or chemotherapy, consent may be obtained prior to transplantation and/or chemotherapy. While the preference is to randomize as soon as possible after eligibility determination, once determined to be eligible for the study, subjects must be consented (if not previously consented) and randomized within 7 days. The 7-day period will start with the <u>first</u> time the patient meets the eligibility criteria as per the <u>report time</u> of the relevant test results. For presumptive invasive tissue bacterial or fungal infections, the 7-day period will start when the clinical team determines that the subject meets all eligibility criteria. RING study staff must document the date and time this decision is made in the subject's study files or medical records. At randomization, the subject's ANC must still be <500/ mm^3 otherwise the subject must not be randomized.

* For randomization, subjects with presumptive fungal infections will not be included in the "mold" stratum but will be included in the "other" stratum. Only proven or probable fungal infections will be included in the "mold" stratum.

5   INTERVENTION

5.1 Infection Documentation

Subjects will have infection documented before randomization, to show that the subject meets the criteria for either

- Bacteremia, OR
- Proven or presumptive invasive bacterial tissue infection, OR
- proven/probable/presumptive invasive fungal tissue infection using the culture, histopathologic, and radiologic criteria as defined in Appendix A.

5.2 Granulocyte Procurement Procedure

<u>G-CSF and dexamethasone administration</u> – G-CSF, 480µg subcutaneously, and dexamethasone, 8mg orally, will be administered 8-16 hours prior to each granulocyte donation, as close to 12 hours prior to donation as is practically possible.

Venous access – peripheral venous access will be used for donors.

Granulocyte collection – granulocytes will be collected by continuous-flow centrifugation. This procedure separates the granulocytes continuously on the basis of differential sedimentation in a centrifuge. Blood will preferably be processed using high molecular weight hydroxyethyl starch (6% Hetastarch in saline 1/12 starch/blood ratio). Pentastarch may be used if hetastarch is not available (10% Pentastarch in saline). For recipients weighing at least 30 kg, seven to ten liters of blood will be processed. Recipients weighing less than 30 kg will receive a proportionally reduced granulocyte dose. Dose reduction may be accomplished by either proportionally reducing the amount of donor blood processed or by transfusion of a proportion of the collected cells. For example, if a recipient weighs 15 kg, either:

- 3.5 to 5 L of blood will be processed and the entire collection will be transfused; OR
- 7 to 10 L of blood will be processed and half of the collection will be transfused.

Granulocyte yield – the number of granulocytes in each granulocyte unit will be determined, with the goal of $\geq 4 \times 10^{10}$ per collection (or proportionately less for subjects under 30 kg).

Gamma irradiation – all granulocyte units will be exposed to a minimum of 2,500 cGy of irradiation to the central plane of the bag with a minimum of 1,500 cGy to any other portion of the bag prior to infusion.

Time to transfusion – all granulocyte units must be available for transfusion as soon as possible. Every attempt will be made to begin transfusion within 6 hours from the completion of collection. A 6-24 hour interval between collection and transfusion is less desirable, but acceptable. Greater than 24-hour interval between collection and transfusion will be considered a protocol violation. All units will be stored at room temperature (20-24°C) without constant agitation.

Cost recovery – the cost of granulocyte procurement, including the cost of the leukapheresis itself as well as the cost of activities required by the study in relation to granulocyte procurement, will be charged to the subject on a cost-recovery basis.

5.3 Administration of Granulocytes
The entire granulocyte product will be infused through a standard blood administration set with a standard blood filter (150 to 280 microns). Leukoreduction filters are not to be used for granulocyte administration. Subjects under 30 kg will receive a maximum of 20 mL/kg. Transfusions will be infused over 1-2 hours as soon as possible (preferably within 6 hours but no longer than 24 hours) after collection. No other blood products will be given during the granulocyte transfusion. Transfusions will be staggered from the administration of any amphotericin B infusion by a minimum of 2 hours. Over a subject's transfusion course, granulocytes will be provided daily if at all possible. Days without granulocyte infusions will be permitted. Responses and subsequent

relapses with the same organism will be considered variations of the same infection and success judged on the status at 42 days after randomization.

If granulocyte transfusions have been discontinued under Section 5.5 (below) and infection with the same or unknown organism recurs or worsens, granulocyte transfusion should be reinstituted if the neutrophil count is <1000 cells/μL . If infection with a known different organism occurs after discontinuation of granulocyte transfusions, transfusions may be restarted at the discretion of the subject's physician if the neutrophil count is <1000 cells/μL.

Subjects in the control arm are not to receive granulocyte transfusions in the 42 days after randomization; if they do receive granulocytes, it will be a protocol violation, but they will still be included in the primary intent-to-treat analysis as a control subject. They will be excluded in the secondary per-protocol analysis of the primary outcome (see Section 8.2).

5.4   Antimicrobial and Adjunctive Measures during the Study Period
Antimicrobial therapy is broadly defined as therapy within the standard of care for a particular infection. Investigational antimicrobial agents are also permitted during the course of the study period, but must be recorded as such. Antimicrobial strategies should be consistent within a given institution. Recommended therapy for specific infections such as invasive mold or candidal disease is noted in Appendix A. Central line removal is recommended for subjects with 2 or more positive blood cultures of *Candida spp.* or *Fusarium spp.* Growth factors (G-CSF) may be administered at the discretion of the attending physician, but should be discontinued if the ANC exceeds 2500/μL for two consecutive days. Data on growth factor use in both treatment groups will be collected by the study.

5.5   Discontinuation of Granulocyte Therapy
Granulocyte transfusions will be given every day to those randomized to the granulocyte arm (when possible), until one of the following conditions is met:

Recovery from neutropenia – if two successive next-morning ANCs rise to $\geq$ 3000 cells/μL, the subsequent (third) day's granulocyte transfusion will be held to determine whether recovery from neutropenia is occurring. Recovery will be defined as the first of two consecutive days with an ANC > 1000 cells/μL without granulocyte support.

Life-threatening toxicity – in the case of life-threatening toxicity, granulocytes will be discontinued immediately and will not be restarted. Such toxicity is expected to occur most often as a serious pulmonary reaction.

Resolution or improvement of underlying infection – at the discretion of the treating physician, but only if the subject has received at least five granulocyte transfusions over a minimum of seven days, granulocyte transfusions may be discontinued prior to recovery from neutropenia and in the absence of toxicity if complete or partial response has occurred. In this circumstance, transfusions should be re-instituted if infection with the same organism recurs or worsens, provided that ANC recovery has not yet occurred.

6 MEASUREMENT AND ACTIVITIES

6.1 Schedule of Subject Measurement
Subjects will be followed until 3 months after randomization or until death, whichever comes first.

Following is a list of the data that will be collected while the subject is on this study. Table 1a and 1b outline the schedule of measurements and section 6.3 provides additional details regarding measurement procedures.

1. **Screening (after consent and prior to randomization)**
   - Documentation of Inclusion/Exclusion criteria including:
     – Infection diagnosis documentation and treatment (refer to Appendix A)
     – Documentation of severe neutropenia (ANC < 500/mm^3) due to marrow failure caused by underlying disease or therapy
     – Duration of pre-existing neutropenia
   - Laboratory
     – Absolute neutrophil count (ANC)

2. **Baseline (within 24 hours after randomization, but before any granulocyte transfusion)**
   - Demographic and medical history
   - Signs and symptoms documentation with narrative
   - Collection for central laboratory
     – Serum for HLA and granulocyte-specific antibodies
     – Serum for fungal antigens (only applicable for subjects with a proven, probable or presumptive fungal infection as the study qualifying infection)

3. **Daily (until time point specified below)**
   - Maximum temperature: daily until discharge or Day 42, whichever comes first
   - Morning ANC: daily until engraftment, discharge or Day 42, whichever comes first (see item #4)
   - Subjects with bloodstream infection, blood culture: daily until 2 consecutive negative tests, discharge or Day 42, whichever comes first
   - Results of available imaging studies and diagnostic tests documenting infection: until discharge or Day 42, whichever comes first
   - Documentation of medications given to treat infection: until discharge or Day 42, whichever comes first
   - Documentation of G-CSF administration (if any): until discharge or Day 42, whichever comes first

4. **Weekly after engraftment**
   - Morning ANC: weekly until discharge or Day 42, whichever comes first

5. **Day 7 ± 2 days**
   - Collection for central laboratory (if hospitalized)

- Serum for fungal antigens (only applicable for subjects with a proven, probable or presumptive fungal infection as the study qualifying infection)

6. **Day 14 ± 2 days**
   - Signs and symptoms documentation, narrative strongly recommended (in hospital or by phone if discharged)
   - Collection for central laboratory (if hospitalized)
     - Serum for HLA and granulocyte-specific antibodies
     - Serum for fungal antigens (only applicable for subjects with a proven, probable or presumptive fungal infection as the study qualifying infection)

7. **Day 28 ± 2 days**
   - Signs and symptoms documentation, narrative strongly recommended (in hospital or by phone if discharged)

8. **Day 42 ± 2 days**
   - Signs and symptoms documentation with narrative
   - Collection for central laboratory
     - Serum for HLA and granulocyte-specific antibodies
     - Serum for fungal antigens (only applicable for subjects with a proven, probable or presumptive fungal infection as the study qualifying infection)
   - Subjects with bloodstream infection, blood culture
   - Studies documenting status of study-qualifying infection

9. **Day 90**
   - Vital status (whether subject is still alive and if not, date of death)

10. **Each granulocyte transfusion**
    - Laboratory
      - ANC within 4 hours prior to transfusion
      - ANC 30 minutes to 2 hours post transfusion
    - Medications given specifically in preparation for pending transfusion
    - Assessment
      - Vital signs within 15 minutes prior to the start of the transfusion
      - Vital signs within 15 minutes after the start of the transfusion
      - Vital signs once, 45 minutes to 1 hour and 15 minutes after the end of the transfusion
      - Oxygen saturation 15 minutes prior to the start of the transfusion
      - Oxygen saturation 15 minutes after the start of the transfusion
      - Oxygen saturation once, 45 minutes to 1 hour and 15 minutes after the end of the transfusion

Table 1a: Subject measurements

	Screening (after consent, prior to randomization)	Baseline (Within 24 hrs after randomization, but before granulocyte transfusion)	Daily until discharged or Day 42, whichever comes first	Daily until engraftment, discharge or Day 42, whichever comes first	Daily until 2 consecutive negative tests, discharge or Day 42, whichever comes first	As clinically indicated until discharge or Day 42, whichever comes first	Weekly after engraftment until discharge or Day 42, whichever comes first	Day 7 ± 2 days	Day 14 ± 2 days	Day 28 ± 2 days	Day 42 ± 2 days	Day 90
Documentation of inclusion/exclusion criteria	X											
ANC	X			X			X					
Demographics and medical history		X										
Signs and symptoms assessment*		X							X	X	X	
Serum for HLA and granulocyte-specific antibodies		X							X		X	
Serum for fungal antigen**		X						X	X		X	
Maximum daily temperature			X									
Blood culture, if bloodstream infection					X						X	
Studies documenting infection						X					X	
Medications given to treat infection						X						
G-CSF administration						X						
Vital Status												X

*If subject is discharged from hospital prior to Day 42, subject/subject's family will be contacted by phone for signs and symptoms assessment.

** Only applicable for subjects with a proven, probable or presumptive fungal infection

Table 1b: Measurements for each granulocyte transfusion

	Each granulocyte transfusion (GT)	Within 4 hours prior to GT	30min to 2 hours post-GT	Within 15 min prior to start of GT	Within 15 min after start of GT	1 hour ± 15 minutes post GT
Product info and start/stop time of GT	X		X			
Medications given in preparation GT	X					
ANC		X	X			
Oxygen saturation				X	X	X
Temperature, respiration, pulse, BP				X	X	X

6.2 Schedule of Donor-Related Activities

Donors will be followed until immediately after donation. Donors will be studied during each donation.

Following is a list of donor data to be collected. Table 2 outlines the schedule of donor-related activities.

Prior to donor enrollment in trial
1. Medical history
   - Family history of sickle cell disease or variant
   - Donor history of sickle cell disease or variant
   - Blood pressure
   - Diabetes mellitus history
   - Peptic ulcer disease history
   - Lithium therapy history
   - Autoimmune disease history
   - Coronary disease history
   - Deep vein thrombosis or venous thromboembolism history
   - Iritis or episcleritis history
2. Laboratory
   - As required by SOP of blood center

12 ± 4 hours prior to leukapheresis
1. G-CSF and dexamethasone administration
2. Data collection
   - Date and time of G-CSF and dexamethasone administration

Prior to leukapheresis
1. Laboratory
   - CBC with differential
2. Data collection
   - Start date and time of leukapheresis

Post leukapheresis
1. Laboratory
   - Product volume
   - Product CBC and differential
2. Data collection
   - Stop date and time of leukapheresis
   - Adverse Events recorded as reported to local blood center
   - Donor will be given instructions regarding safety follow-up

Table 2: Donor-related activity schedule

	Prior to enrollment	12 ± 4 hours pre-leukapheresis	Immediately pre-leukapheresis	Immediately post-leukapheresis
Consent	X			
Medical history	X			
Laboratory per local SOP	X			
G-CSF/dexamethasone administration		X		
CBC with differential			X	
Start and stop date and time of leukapheresis			X	X
Instructions on possible adverse effects				X
Product volume				X
Product CBC with differential				X

6.3   Measurement Procedures

Protocol-specified procedures will depend on infection type at enrollment, as noted below:

Bloodstream infections – blood cultures will be obtained at a minimum once every 24 hours during the study period (regardless of body temperature) for all subjects entered on study due to fungemia or bacteremia until two consecutive blood cultures remain negative after 72 hours of incubation, in order to determine time to negative test for bloodstream infection.

Invasive tissue fungal or bacterial infections – for subjects with tissue infections, repeat site-directed tissue biopsies or diagnostic procedure such as BAL will be performed only as clinically indicated. For radiographically determined infections (typhlitis, pneumonitis, necrotizing fasciitis, etc), follow-up radiography (e.g., CT scan or other appropriate radiographic technique) will be performed as clinically indicated during the study and again at 40-45 days after randomization to determine response.

Vital signs - case report forms will be completed to capture maximum daily temperature for all subjects. Vital signs will be also be recorded within 15 minutes prior to the start of each granulocyte transfusion, 15 minutes after the start of transfusion, and at 1 hour after transfusion of granulocytes (or more frequently as clinically indicated).

Signs and Symptoms Assessment – will be collected at baseline and Days 14, 28, and 42. If a subject is discharged prior to Day 42, attempts will be made to collect signs and symptoms data by telephone.

Oxygen saturation – granulocyte recipients will be monitored with pulse oximetry within 15 minutes prior to the start of the granulocyte transfusion, 15 minutes after the start of transfusion, and at 1 hour after transfusion of granulocytes, or more frequently as clinically indicated. A 10% decline in O_2 saturation for 5 minutes during the granulocyte infusion will be grounds for suspending the infusion, which can be resumed at 1/2 the rate when the O_2 saturation rises to baseline levels or > 90%. A decline of > 15% in O_2 saturation within 4 hours of the start of the transfusion that cannot be ascribed to causes other than the transfusions will be defined as pulmonary toxicity, and will be grounds for discontinuation of all further transfusions in that subject. Because the co-administration of amphotericin B products and granulocytes may be associated with pulmonary reactions, the administration of amphotericin products will be separated from the transfusions by a minimum of 2 hours.

6.4   Specimen Collecting Procedures

Hematology – all subjects will have daily CBC and differential until three days after engraftment and then at least weekly for the remainder of the 42-day study period. Engraftment is defined for the control subjects as the first of two consecutive days when the subject's absolute neutrophil count exceeds 1000 cells/µL. For subjects in the treatment arm, engraftment is defined as the first of two consecutive days with an ANC > 1000 cells/µL without granulocyte support.

Subjects receiving granulocytes will have CBC and differentials determined for every day of transfusion: pre-infusion, 30 minutes to 2 hours after the infusion.

Antibodies – subjects in both arms of the study will have 5 mL of blood collected at randomization (baseline) and at 14 and 42 days after randomization. From each of these samples, serum (2 mL) will be frozen. With the exception of the collection at baseline, samples may be collected up to 2 days before and until 2 days after these time points. For example, the sample for 14 days after randomization may be drawn from 12 to 16 days after randomization. Testing for HLA antibodies and granulocyte-specific antibodies will be performed on these samples retrospectively.

Serum for fungal antigens – all subjects in both arms of the study with confirmed or suspected study qualifying infection of aspergillosis or a presumptive fungal infection will have 5 mL of blood collected in an EDTA tube at baseline, and at days 7, 14, and 42 after randomization (± 2 days). From each of these samples, serum will be obtained for testing for fungal antigenemia (e.g. galactomannan antigen). The amount of serum obtained shall be the minimum required for the test. A central lab will test all baseline samples for the presence of circulating fungal antigenemia. Those subjects with fungal antigenemia present at baseline will have their remaining samples tested to determine the time to clearance. The non-baseline samples for subjects that do not have fungal antigenemia present at baseline will be destroyed.

6.5 Adjudication Procedures

A blinded adjudication panel will be convened at the interim efficacy analysis and at the conclusion of the trial. The panel performing the study adjudication, consisting of three infectious disease specialists and one radiologist, will not be informed of the subject's treatment group. Adjudication will address the following three items:

a. Whether the subject was actually eligible for the study
b. The appropriateness of the antimicrobial therapy administered, including any surgical therapy
c. Whether or not there was a response

Adjudication findings will be recorded on the appropriate case report form. These decisions will be based on clinical summaries, laboratory results, cultures, reports of imaging studies (X-rays, CT, MRI), and data from the standard case report forms.

7   ADVERSE EVENT CRITERIA AND REPORTING

Reporting of all adverse events will follow the standard TMH CTN procedures described in the TMH Manual of Procedures (MOP), Chapter 6: Guidelines for Reporting Adverse Events. Reporting requirements are calibrated to the seriousness of the event and the perceived relationship to the study drug/device/treatment(s) (granulocyte transfusion, G-CSF, dexamethasone or granulocyte collection procedure). For this study the reporting requirements will be based on the type and severity of adverse event.

The TMH CTN will be using the descriptive terminology developed by the National Cancer Institute for use in reporting adverse events: Common Terminology Criteria for Adverse Events (CTC) version 3.0 dated December 12, 2003. The CTC includes a grading (severity) scale for each adverse event term. Grades were developed using the following guidelines:

Grade 0 - No adverse event or within normal limits
Grade 1 - Mild adverse event
Grade 2 - Moderate adverse event
Grade 3 - Severe adverse event
Grade 4 - Life threatening or disabling adverse event
Grade 5 - Death related to adverse event

In general, investigators should report adverse events as diseases or syndromes whenever possible, instead of reporting individual component symptoms, signs, laboratory abnormalities, and sequelae.

7.1   Definitions

Adverse Event (AE) – any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medical treatment or procedure regardless of whether or not it is considered related to the medical treatment or procedure (attribution of unrelated, unlikely, possible, probable, or definite).

Life-threatening Adverse Event – any adverse event that, in the opinion of the investigator, places the subject or the granulocyte donor at immediate risk of death.

Serious Adverse Event (SAE) – any adverse event that results in any of the following outcomes: death, a life-threatening event, inpatient hospitalization or prolongation of existing hospitalization, congenital anomaly/birth defect, and/or a persistent or significant disability/incapacity.

Unexpected Adverse Event – any adverse event attributed to be possibly, probably, or definitively related to one of the following: granulocyte transfusion, G-CSF, dexamethasone, or the granulocyte collection procedure; the specificity or severity of which is NOT listed in the study protocol, product inserts, or informed consent document.

Attribution – the determination of whether an adverse event is related to a medical treatment procedure.

Attribution categories:
1. *Definite* – the adverse event is clearly related to the study drug/device/treatment(s).
2. *Probable* – the adverse event is likely related to the study drug/device/treatment(s). The adverse effect is not likely to be caused by the subject's underlying medical condition or other concomitant therapy, and the nature of the adverse event or the temporal relationship between the onset of the adverse event and study drug/device/treatment(s) administration lead the investigator to believe that there is a reasonable chance of causal relationship.
3. *Possible* – the adverse event may be related to the study drug/device/treatment(s). The adverse event could be attributed to the subject's underlying medical condition or other concomitant therapy, but the nature of the adverse event or the temporal relationship between the onset of the adverse event and study drug/device/treatment(s) administration lead the investigator to believe that there could be a causal relationship.
4. *Unlikely* – the adverse event is doubtfully related to the study drug/device/treatment(s).
5. *Unrelated* – the adverse event is clearly NOT related to the study drug/device/treatment(s). The adverse event is most plausibly explained by the subject's underlying medical condition or other concomitant therapy.

7.2 Adverse Events in Subjects

Information about the following adverse events that occur in subjects will be collected:

1) Serious adverse events, regardless of attributed relationship to granulocyte transfusion
2) Any unexpected adverse event (all grades), attributed as possibly, probably or definitely related to granulocyte transfusion
3) Granulocyte Transfusion Events

7.2.1 Expedited Reporting of Adverse Events in Subjects

Serious adverse events and all unexpected adverse events will be reported to the Data Coordinating Center (DCC) within 24 hours of occurrence by phone or email. Such adverse events will be recorded on a Serious/Unexpected Adverse Event form and faxed to the DCC within 48 hours of the occurrence. A summary of the event will be reported within 10 days of occurrence. Data on serious and unexpected adverse events in subjects will be collected through end of study.

7.2.2 Regular Reporting of Adverse Events in Subjects

Adverse events of all grades that occur during the transfusion of granulocytes or within six hours after the end of a granulocyte transfusion will be monitored by the DCC for all subjects who receive granulocyte transfusions, using data reported on the Granulocyte Transfusion Event form. These events include: allergic reaction/hypersensitivity, sinus bradycardia, sinus tachycardia, hypertension, hypotension, dyspnea, hypoxia, wheezing, cough, hemolysis, fever, infection, and rigors/chills. Sites will data-enter Granulocyte Transfusion Event forms within two weeks of the occurrence of the adverse event. Serious granulocyte transfusion events and unexpected granulocyte transfusion events are also reported within 24 hours as described in Section 7.2.1.

7.2.3 Monitoring of Serious and Unexpected Adverse Events in Subjects

Serious adverse events and all unexpected adverse events must be reported to the Data Coordinating Center (DCC) in an expedited manner, irrespective of the attribution of the event to the study drug/device/procedure/treatment.

Serious adverse events and all unexpected adverse events will be promptly reviewed by the Medical Monitor at, or associated with, the DCC. The Medical Monitor has medical expertise relevant to the study protocol and may request the subject's treatment assignment when reviewing the adverse event.

The Medical Monitor or DCC representative is responsible for notifying the NHLBI Project Officer of all serious and unexpected adverse events, and of any concerns regarding the frequency or type of adverse event(s) on a study or study treatment arm. The NHLBI Project Officer will be notified immediately if an event is determined to be possibly, probably, or definitively related to a granulocyte transfusion; additionally, information about the adverse event will be included in the monthly summary report. If an event is determined to be unrelated or unlikely related to a granulocyte

transfusion, it will be included in the monthly summary report (see Figure 2).

The NHLBI Project Officer (or designee) is responsible for reviewing the adverse event materials to determine if the materials are complete. If there are any concerns regarding the type or frequency of the event, the NHLBI Project Officer will request that the DSMB Executive Secretary notify the DSMB Chair. The DSMB Chair will review the adverse event materials, determine if the information is complete, determine if additional DSMB review is required, and make recommendations to the NHLBI concerning continuation of the study. Full documentation of the procedures will be available at the DCC.

The DCC will prepare monthly summary reports of all serious and unexpected adverse events for the NHLBI Project Officer.

7.2.4 Monitoring of Adverse Events Associated with Granulocyte Transfusions

Adverse events of all severity levels that occur during the transfusion of granulocytes or within six hours after the end of a granulocyte transfusion (e.g. events related to allergic reaction/hypersensitivity, sinus bradycardia, sinus tachycardia, hypertension, hypotension, dyspnea, hypoxia, wheezing, cough, hemolysis, fever, infection, and rigors/chills) will be reported on Granulocyte Transfusion Event forms, which will be data-entered within two weeks of the event's occurrence. Serious and unexpected granulocyte transfusion events are also reported within 24 hours, and monitored as described in Section 7.2.1.

The cumulative frequency of granulocyte transfusion events of Grade 3 or higher will be determined each quarter by the DCC. The DCC Protocol Statistician will calculate the percentage of subjects with at least one granulocyte transfusion event of Grade 3 or higher among those subjects who receive granulocyte transfusions. The Protocol Statistician and Medical Monitors will meet to review and discuss the results of this analysis. Granulocyte transfusion events of Grade 3 or higher are expected to be rare. In this subject population, approximately 5% of subjects receiving granulocytes would be expected to have at least one such event. If 20% of subjects receiving granulocytes experience a Grade 3 or higher transfusion event, the DCC will notify the NHLBI Project Officer, who will request that the DSMB Executive Secretary contact the DSMB chair (see Figure 2). This monitoring plan is designed to identify a possible excess of transfusion events; it is not intended to serve as a formal stopping rule for this study.

Figure 2: Adverse Event Monitoring Plan for Subjects

Serious or Unexpected Adverse Event includes serious granulocyte transfusion events	**Granulocyte Transfusion Event**

↓ ↓

Expedited Reporting Reported to the DCC within 24 hours of occurrence by phone or email; SAE form faxed within 48 hours; summary of event within 10 days	***Regular Reporting*** Data Recorded on a Granulocyte Transfusion Event form; site enters form into Data Management System within two weeks of occurrence

↓ ↓

Medical Monitor reviews serious or unexpected adverse event upon receipt of data	Quarterly calculation of % of cumulative subjects who receive granulocytes and experience a Granulocyte Transfusion Event of Grade 3+. Analysis will be reviewed by Medical Monitor(s) and Statistician

↓	↓	↓	↓
Serious Adverse or Unexpected Event unrelated or unlikely related to transfusion of granulocytes according to site and Medical Monitor	Serious Adverse or Unexpected Event possibly, probably, or definitely related to transfusion of granulocytes according to site or Medical Monitor	≥20% of subjects with Grade 3+ event	<20% of cumulative subjects with Grade 3+ event

↓	↓
Additional Medical Monitor reviews monthly	Additional Medical Monitor reviews immediately

↓	↓
NHLBI notified monthly	NHLBI notified immediately

NHLBI notified quarterly

↓

NHLBI may notify DSMB Chair

↓

Possible DSMB meeting

7.3 Adverse Events in Donors

Information about serious adverse events, regardless of relationship to G-CSF, dexamethasone, or granulocyte collected procedure, that occur in donors will be collected. All known serious adverse events that occur from immediately after G-CSF and dexamethasone administration to one week after administration will be reported.

Figure 3 summarizes the donor monitoring in this study.

7.3.1 Expedited Reporting of Adverse Events in Donors

Serious adverse events will be reported to the DCC within 24 hours of occurrence by phone or email. Such adverse events will be recorded on a Serious/Unexpected Adverse Event form and faxed to the DCC within 48 hours of the occurrence. A summary of the event will be reported within 10 days of occurrence.

7.3.2 Monitoring of Serious Adverse Events in Donors

Serious adverse events must be reported to the Data Coordinating Center (DCC) in an expedited manner, irrespective of the attribution of the event to the study drug/device/procedure/treatment.

Serious adverse events will be promptly reviewed by the Medical Monitor at, or associated with, the DCC. The Medical Monitor has medical expertise relevant to the study protocol.

The Medical Monitor or DCC representative is responsible for notifying the NHLBI Project Officer of all serious adverse events, and of any concerns regarding the frequency or type of adverse event(s) on a study. The NHLBI Project Officer will be notified immediately if an event is determined to be possibly, probably, or definitively related to a granulocyte donation; additionally, information about the adverse event will be included in the monthly summary report. If an event is determined to be unrelated or unlikely related to a granulocyte donation, it will be included in the monthly summary report (see Figure 3).

The NHLBI Project Officer (or designee) is responsible for reviewing the adverse event materials to determine if the materials are complete. If there are any concerns regarding the type or frequency of the event, the NHLBI Project Officer will request that the DSMB Executive Secretary notify the DSMB Chair. The DSMB Chair will review the adverse event materials, determine if the information is complete, determine if additional DSMB review is required, and make recommendations to the NHLBI concerning continuation of the study. Full documentation of the procedures will be available at the DCC. In the event of a donor death, study accrual will be suspended immediately, pending review by the DSMB.

The DCC will prepare monthly summary reports of all serious adverse events for the NHLBI Project Officer.

Figure 3: Adverse Event Monitoring Plan for Donors

Serious Adverse Event

↓

Expedited Reporting Reported to the DCC within 24 hours of occurrence by phone or email; SAE form faxed within 48 hours; summary of event within 10 days

↓

Medical Monitor reviews serious or unexpected adverse event upon receipt of data

↓   ↓

Serious Adverse Event unrelated or unlikely related to G-CSF, dexamethasone, and/or collection of granulocytes according to site and Medical Monitor	Serious Adverse Event possibly, probably, or definitely related to G-CSF, dexamethasone, and/or collection of granulocytes according to site or Medical Monitor

↓   ↓

Additional Medical Monitor reviews monthly	Additional Medical Monitor reviews immediately

↓   ↓

NHLBI notified monthly	NHLBI notified immediately

↓

NHLBI may notify DSMB Chair

↓

Possible DSMB meeting

7.4 Data Collection and Validation

Data will be collected and entered into a web-based data management system (DMS) at each site participating in the TMH Granulocyte Study, and transferred electronically to the Data Coordinating Center. The DMS is programmed to validate all data entry fields as the data are entered. Validations are question-by-question checks that give immediate feedback to help catch data entry errors, form completion errors, and out-of-range values. Reports of outstanding edits, generated upon completion of data entry, will enable continuous cleaning of data at each site.

The DCC will regularly monitor all data for consistency and correctness. If the DCC observes inconsistent data or patterns of protocol violations or missing data, site staff will be contacted immediately to address the finding.

Data Collection Instruments – study personnel at each site will enter data from source documents corresponding to a subject's visit onto case report forms. All information contained in the case report form will be entered into the study database.

Confidentiality – each subject and donor is assigned a unique number to assure confidentiality. Any publication or presentation will refer to subjects and donors by this number and not by name. The medical records department, affiliated with the institution where the subject receives medical care, maintains all original inpatient and outpatient chart documents. Subject research files will be kept in a locked room.

Data Management – NERI will serve as the trial coordinator for this study. NERI will monitor timely entry of data into the study database. Access to all source documentation maintained by the Investigator, including correspondence and source data, will be available for monitoring and audit purposes.

Data archives – at all times, appropriate backup copies of the database and related software files will be maintained and the information will be appropriately protected from illegitimate access.

7.5 Expected Adverse Events in Subjects

Certain adverse events are common and expected in the setting of chemotherapy, HSC transplantation and various marrow failures; however, these toxicities are generally not likely to be due to the administration of the granulocyte product and will not undergo reporting as an adverse event. Toxicities that will not undergo adverse event reporting include:

- Fatigue
- Fever
- Anorexia (as defined under "Gastrointestinal")
- Mucositis
- Hypokalemia
- Anemia, leukopenia, thrombocytopenia

Recipients of marrow or PBSC transplants incur risks from pre-transplant conditioning, the graft itself, and post-transplant therapies. Major risks following transplantation include:

- Damage of any major organ may occur as a result of cumulative toxicity from anti-neoplastic therapy, the conditioning regimen, drug toxicity, infection, or GVHD.
- Graft failure can result from genetic disparity between donor and recipient,
- GVHD can be either acute or chronic; both types predispose to infection.
- Life-threatening infections may develop in subjects with and without GVHD. These can be of a bacterial, viral, parasitic, or fungal nature.
- Relapse of the underlying disease may occur, especially in subjects with far advanced disease status at time of transplant.

All of these toxicities may be severe enough to result in death.

Subjects undergoing aggressive chemotherapy incur the following major risks:

- Damage of any major organ may occur as a result of cumulative toxicity from anti-neoplastic therapy, drug therapy, or infection.
- Life threatening infections may develop. These may be bacterial, viral, parasitic, or fungal.
- Relapse of the underlying disease may occur.

All of these toxicities may be severe enough to result in death.

Subjects receiving granulocyte transfusions incur the following major risks:

- Anaphylaxis
- Acute lung injury
- Transmission of infectious disease

All of these toxicities may be severe enough to result in death.

In addition to the adverse events listed above, Appendix C lists events that are considered expected in the setting of chemotherapy, HSC transplantation or various marrow failures, and will not be reported. However, if any event meets the definition of a serious adverse event (see Section 7.1), it must be reported as specified in Section 7.2.1.

7.6   Expected Adverse Events in Donors

Donors undergoing G-CSF/dexamethasone stimulated leukapheresis procedures incur the following major (although extremely rare) risks:

- Splenic rupture
- Moderate/severe rash
- Persistent moderate/severe thrombocytopenia
- Severe aching, bone pain, etc that requires further medical attention
- Sickle crisis
- Thromboembolic event
- Coronary event
- Exacerbation of underlying inflammatory/autoimmune disorder

Several of these toxicities may be severe enough to result in death.

Risks Related To Dexamethasone – The side effects of dexamethasone may include insomnia, an increase in appetite, euphoria, depression, fluid

accumulation, and weight gain. Corticosteroids have been reported to cause cataracts in the eyes when given to patients for treatment of disease. Whether this is a risk for healthy granulocyte donors is unknown. Two studies of granulocyte donors showed no definite increase in cataract risk, but the trends did suggest a possible relationship. Cataracts in these studies were tiny, did not impair vision, and were detected only by special eye examinations. Because there is no established risk of cataracts in granulocyte donors, no general recommendations can be made.

Risks related to hydroxyethyl starch – The side effects of hydroxyethyl starch may include allergic reaction, fluid accumulation, and weight gain.

7.7 Reporting and Management
Study participants will be receiving potentially toxic preparative therapy, and significant regimen-related toxicity is anticipated. Study Case Report Forms (CRFs) are designed to capture information on these adverse events. Likewise, substantial mortality is anticipated and will be captured via filing of appropriate CRFs. All unexpected adverse events will be reported for the duration of the study.

7.7.1 Interim Reporting
This section describes scheduled reports that will be sent to the study sites and the DSMB. Reporting requirements for events that will be monitored continuously (e.g. unexpected serious adverse events) are described above.

7.7.1.1 Monthly Reports to Sites
Reports of accrual information, outstanding queries, and protocol violations will be distributed to the sites monthly

7.7.1.2 Quarterly DSMB Reports
The DSMB will receive quarterly updates on:
- Site status;
- Accrual overall and by site;
- Study compliance issues; and
- The status of adverse event monitoring:
  - The cumulative percentage of subjects in the granulocyte arm with at least one Grade 3+ transfusion-related event, if the cumulative percentage is $\geq$20%;
  - The types and frequencies of Grade 3+ transfusion-related events, if the cumulative percentage of subjects with such events is $\geq$20%;
  - All reported adverse events in donors
  - Whether the continuous review or monthly discussion raised issues that were reported to NHLBI as being of possible concern; and
  - Any actions taken in response to those concerns

7.7.1.3 Semi-Annual DSMB Reports
The DSMB will meet every 6 months, either in-person or via teleconference. Reports will include:
- Baseline characteristics overall and by treatment arm;

- Serious adverse events overall and by treatment arm;
- Transfusion related events of all severity levels for subjects randomized to granulocyte transfusions;
- Site status;
- Accrual overall and by site; and
- Study compliance issues.

7.7.1.4 Other DSMB Reports

The DSMB will receive the results of a formal interim analysis of the primary endpoint after half the planned subjects have completed 42 days of follow-up (see Section 8.5.1).

The DSMB will receive the results of a formal interim analysis of death rates in the two arms each time the total number of deaths increases by 14 (see Section 8.5.2).

8 STATISTICAL CONSIDERATIONS

8.1 Baseline Characteristics

Demographic and other baseline characteristics of subjects in the two treatment arms will be described.

8.2 Analyses for the Primary Endpoint

The primary evaluation of the primary endpoint will follow the intention-to-treat principle. Therefore, when the data are analyzed, patients who are randomized to receive only antimicrobial therapy but receive some granulocytes will be included in the control group, while those who are randomized to the granulocyte group but who do not receive granulocytes or who receive less than the prescribed regimen of granulocytes will be included in the granulocyte group. The rate of primary endpoints in the two treatment groups will be compared using Fisher's exact test. This test was selected instead of the chi-square test to allow for the possibility that the number of treatment failures may be too small to justify the assumed large sample properties of the chi square test, especially at an interim look.

A secondary analysis will be restricted to those subjects who meet both of the following criteria: 1) survive 3 days after randomization and 2) are retrospectively determined by the adjudication panel to have been eligible for enrollment. In this analysis we will explore the relationship between the granulocyte dose delivered and survival.

A secondary, per-protocol, analysis will also be conducted that will include only those subjects who receive their assigned treatments as described in the protocol. This analysis will exclude

- Subjects who are randomized to only receive antimicrobial therapy but receive one or more granulocyte transfusions in the 42 days after randomization;

- Subjects who are randomized to receive granulocyte transfusions, but refuse to receive them. (Subjects who are randomized to receive granulocyte transfusions but do not receive them, or have them discontinued, for reasons specified in the protocol will be included, i.e. patients who experience recovery from neutropenia, life-threatening toxicity, resolution or improvement of infection, unavailability of granulocytes, or death before granulocyte transfusion can occur); and
- Subjects who did not receive appropriate organism-directed antimicrobial therapy, as determined by the adjudication committee. (See Section 6.5)

If there are baseline characteristics associated with the primary endpoint then another secondary analysis will be conducted using exact logistic regression to adjust for the differences in distribution of the baseline traits.

8.3 Analyses for Secondary Endpoints

8.3.1 Safety of granulocyte transfusions

8.3.1.1 Alloimmunization

Alloantibody profiles (anti-HLA and anti-neutrophil) will be obtained from each subject at randomization and after 14 and 42 days on study (± 2 days). Each subject will be scored for the emergence of new alloantibodies by comparing the profiles at the start and end of each of the two intervals defined by these time points. The scores will be treated as binary variables (presence/absence of new antibodies during an interval). A subject may develop new alloantibodies during multiple intervals, but the major issue of interest is whether the subject developed any new alloantibodies at any time during the follow-up period. Therefore, the analysis will focus on time to first new alloantibody. Treatment arms will be compared using the approach developed by Gray [33], which accounts for competing risks. In this case, the competing risk is death. A routine for the cumulative incidence function and Gray's test is currently available in the R library. The approach developed by Hudgens et al. [35] will be employed to take account of the interval censoring inherent in the scheduled observations.

8.3.1.2 Serious transfusion reactions

This safety endpoint applies only to subjects who receive granulocyte transfusions. Serious transfusion reactions that are attributed to granulocyte transfusions will be tabulated and the frequency distribution of the number of serious transfusion reactions per subject will be derived. Analyses will be done to assess whether the reactions are randomly distributed among subjects and transfusions. This analysis will be adjusted for the number of transfusions each subject receives.

8.3.1.3 Graft vs. Host Disease

The incidence of GvHD will be compared between treatment arms using the cumulative incidence functions described earlier for alloimmunization. In this case, however, no adjustment for interval censoring will be needed. Graphs of cumulative incidence vs. time, which are similar in form to Kaplan-Meier plots but take account of the competing risk, will also be produced (see Marubini and Valsecchi [34]). The comparison will be limited to subjects with allogeneic stem cell transplantation. Follow-up for this endpoint will be censored at 42 days.

8.3.1.4 Adverse events

The type and number of serious adverse events in each arm will be tabulated, as will the type, number and severity of events related to granulocyte transfusions. The formal interim monitoring plan for safety, however, focuses only on mortality (see Section 8.5.2).

8.3.1.5 Discontinuation of transfusions due to toxicity or intolerance

This safety endpoint applies only to subjects who are randomized to receive granulocyte transfusions. The number of subjects for whom granulocyte transfusions must be discontinued because of toxicity or intolerance will be tabulated. The risk of discontinuation will be described by developing a Kaplan-Meier plot using the number of transfusions, rather than time on study, as the measure of exposure. Subjects will be censored at 42 days, at death, or when transfusion treatment is halted for reasons other than toxicity or intolerance, whichever occurs first.

8.3.2   Efficacy Outcomes

8.3.2.1 Outcome within infection subgroups

The rates of primary endpoints in the two treatment arms will be compared separately for subjects in each of the following subsets.
- All invasive mold infection (proven, probable, and presumptive)
- Proven or probable mold infection
- Presumptive mold infection
- Mold pneumonia (including proven, probable, and presumptive)
- Mold extrapulmonary (including proven, probable, and presumptive)
- Mold disseminated (i.e. 2 or more distinct sites)
- Bacteremia
- Fungemia
- Bacterial tissue infection

Fisher's exact test will be used for the comparisons. In general, these subsets are not mutually exclusive, so treatment effects will not be compared among them. However, an interaction test will be performed to compare treatment effects in subjects whose study-qualifying infection is proven or probable mold infection vs. subjects whose study-qualifying infection is presumptive mold infection.

8.3.2.2 Time to resolve fever

Analysis of time to resolution of fever, for subjects with fever at baseline, will follow the methods that will be used for GvHD (Section 8.3.1.3). Fever

resolution in the two treatment arms will be compared using Gray's model [33] to account for the competing risk of death. An appropriate routine is currently available in the R library. Graphs of cumulative incidence vs. time will also be produced (Marubini and Valsecchi [34]). Follow-up for this endpoint will be censored at 42 days.

8.3.2.3 Time to clear antigenemia

Tests for antigenemia will be performed at baseline for all subjects with confirmed or suspected aspergillosis as the study qualifying infection. Subjects with fungal antigenemia present at baseline will then have their day 7, 14, and 42 samples tested as well. Time to clear circulating fungal antigenemia will be assessed in subjects with fungal antigenemia present at baseline (e.g. galactomannan antigenemia among subjects with invasive aspergillosis). Clearance times in the two treatment arms will be compared using cumulative incidence functions with adjustment for interval censoring as described above for development of alloantibodies.

8.3.2.4 Time to negative blood culture

Analysis of time to negative blood culture, for subjects with a positive blood culture at baseline, will follow the methods that will be used for GvHD (Section 8.3.1.3). Time to negative blood culture in the two treatment arms will be compared using Gray's model [33] to account for the competing risk of death. An appropriate routine is currently available in the R library. Graphs of cumulative incidence vs. time will also be produced (Marubini and Valsecchi [34]). Follow-up for this endpoint will be censored at 42 days.

8.3.3 Long term survival

Though overall survival often primarily reflects disease status (rather than response to anti-infective therapy), we will compare survival through 3 months after randomization using a Kaplan-Meier plot and a log-rank test.

8.3.4 Donor Endpoints

8.3.4.1 Donor safety

The types and number of adverse events reported by donors will be tabulated. Analyses will be done to assess whether serious adverse events are randomly distributed among donors and donations. If so, the risk per donation of each type of serious adverse event, and of any serious adverse event, will be estimated.

8.3.4.2 Donor availability

Donor availability may be an important consideration in judging the feasibility of a granulocyte transfusion program. Therefore, the proportion of scheduled transfusion days on which granulocytes were available, overall and at each treatment center, will be calculated. The proportion of scheduled transfusion days on which granulocytes were available will also be calculated for each subject and the frequency distribution of these proportions will be derived overall and at each treatment center.

8.3.5 Evaluation of granulocyte yield

Descriptive statistics will be calculated for the number of granulocytes collected per donation. If a full donation is not attempted because the intended recipient is under 30 kg, this will be taken into account. For example, if 5 liters of blood are processed rather than 10 liters, because the intended recipient weighs 15 kg, and the total yield of the donation is 4×10^{10}, then the yield will be considered to be 8×10^{10} for purposes of these analyses.

8.4   Sample Size and Power Calculations

Successful outcome for the aggregate control population in the current era (based upon Hubel et al [20] and Nichols et al [25]) is expected to be approximately 50%. Given the expense and potential toxicity of the approach, we have designated a 20% absolute difference in the rate of primary endpoints as the minimum that could be deemed clinically significant (70% success rate). We have designed this study with 80% power to detect this difference (alpha=0.05, two sided), which yields a sample size of 103 subjects per arm. To account for a small percent of misdiagnoses (estimated at 5%) and the effect of interim analysis on the Type I error, we have inflated the sample size to 118 subjects per arm, i.e. 236 total subjects.

Although the target sample size is 236 randomized subjects, it is possible that the actual final sample size may fall short of this goal. Figure 4a shows the power to detect an absolute treatment difference of 20% over a range of sample sizes from 100 randomized subjects to 236 randomized subjects, and over a range of control group success rates from 40% to 60%. If more than 120 subjects are randomized, there will be over 50% power to detect a 20% absolute improvement in the success rate. In other words, if the true treatment difference is 20%, the study will be more likely than not to find a statistically significant treatment group difference. Figure 4b shows the power to detect an absolute treatment difference of 25% over the same range of sample sizes and control group success rates. To detect a treatment difference of this size, the power is over 50% for all scenarios considered, and the power will be 80% or more if at least 160 subjects are randomized.

Figure 4a. Power to detect a 20% absolute improvement in the proportion of subjects with treatment success, over a range of sample sizes and control group success rates.


Figure 4b. Power to detect a 25% absolute improvement in the proportion of subjects with treatment success, over a range of sample sizes and control group success rates.

8.5 Interim Analysis

8.5.1 Interim Analysis for Efficacy and Futility

Interim monitoring for both efficacy and futility will be employed in this trial. If there is strong evidence at an interim analysis that subjects in one arm are much more likely to succeed than subjects in the other arm (using the primary outcome as the definition of success) it may be ethical to halt the trial early. Because of the cost and potentially serious adverse effects of granulocyte transfusions, it would also be difficult to justify continuing a trial if there was strong evidence at an interim analysis that the null hypothesis of no treatment effect is very unlikely to be rejected. Efficacy and futility are monitored simultaneously using a single test statistic at each monitoring point.

Two interim analyses are planned, after 80 subjects (33% accrual) and after 160 subjects (67% accrual) have data on the primary study endpoint (success or failure by Day 42). Lan-DeMets spending functions that approximate O'Brien-Fleming boundaries will be used. The critical p-values for this plan, assuming statistical power of 0.80 and a two-tailed Type I error rate of 0.05, are listed in Table 3. P_{1k} and P_{2k} denote the critical values for efficacy and futility respectively at each look. As is characteristic of O'Brien-Fleming boundaries, stronger evidence (more extreme p-values) are required at the earlier analyses than at the later analyses. At the final analysis, $P_{1K}=P_{2K}$ which means that one hypothesis or the other must be rejected.

Table 3: Critical p-values for rejecting the null and alternate hypotheses at three equally-spaced analyses

Analysis (k)	% of final sample size	P_{1k} (reject H_0)	P_{2k} (reject H_1)
1	33	0.0002	0.9659
2	67	0.0121	0.3444
3	100	0.0501	0.0501

Adding interim monitoring for efficacy and futility slightly inflates the maximum number of subjects the study must plan for. However, this interim monitoring plan reduces the expected number of subjects that will actually need to be enrolled, because the trial may halt for efficacy or futility at one of the interim looks.

8.5.2 Interim Analyses for Safety

Expected and unexpected adverse events and serious adverse events will be monitored, with regular reports to NHLBI for consideration by the DSMB, as described in Section 7. Statistical monitoring for safety will be limited to comparisons of death rates through 42 days of follow-up in the two treatment arms. This interval was chosen so that the comparison would focus on the interval during which subjects randomized to granulocyte transfusion would be receiving treatments, on the assumption that any effect (positive or negative) of granulocyte transfusions on the risk of death would likely be realized during this interval. Given the severity of the underlying condition of the subjects in this trial and the

expected high mortality rate in the control arm, an excess of deaths in one treatment arm was considered the only safety concern that would lead to halting the trial. An excess of nonfatal serious adverse events in one arm may be acceptable if that arm also has a lower mortality rate.

The problem of developing a monitoring plan is complicated by the lack of information on which to base reasonable predictions of the magnitude and the direction of a difference in death rates between treatment arms. The infectious disease specialists who provided input to protocol development indicated that 30-40% of subjects in the control arm would be expected to die within 42 days. The death rate that should be expected in subjects randomized to granulocytes is unclear. Serious adverse reactions to granulocytes could result in an increase in the death rate. On the other hand, if granulocyte transfusions promote clearance of infections, then the death rate in the transfusion arm could be lower than the death rate in the control arm.

The following monitoring plan was approved by the DSMB. Rather than comparing death rates at specific time points, analyses will take place after specified total numbers of deaths have occurred. An interim analysis will be performed after each increment of 14 total deaths in the study (e.g. after 14, 28, 42, etc. total deaths). Fisher's exact test will be employed to compare the proportions dying in the two arms through 42 days of follow-up. This test was chosen because the number of events at the earliest interim analyses is unlikely to be large enough to justify the assumptions underlying approaches, such as the chi-square test, that depend on large sample properties. Two-tailed tests will be used because the expected direction of the difference in death rates is unknown. A flat p-value boundary of 0.02 will be used at each test. NHLBI will be notified of the results of each analysis. If a p-value < 0.02 is found at any interim analysis, NHLBI will request that the DSMB discuss the possibility of halting the trial. This flat monitoring boundary was selected because the focus is on subject safety. Monitoring boundaries, such as the O'Brien-Fleming boundary, that require stronger evidence to halt a trial at earlier analyses than at later time points seem less appropriate when the endpoint is subject safety.

The operating characteristics of this design, and a number of other potential designs, were investigated in a series of simulations. Parameters investigated were
a) performing analyses after every 6 deaths, every 10 deaths, or every 14 deaths
b) using 0.01, 0.015, 0.02, 0.03, or .004 as the critical value
c) death rates in the control arm of 0.30, 0.40, or 0.50
d) between-arm differences in death rates of -0.20, -0.10, 0.00, 0.10, or 0.20

For each scenario, 5,000 replications were run.

The proposed design was chosen because it provides
• a Type I error rate close to 0.05 under a wide range of scenarios

- good power to detect an absolute difference in death rates of at least 20% (either at an interim analysis or at the end of the study) if the study reaches its target sample size
- a high probability of halting early if the true death rates have an absolute difference of at least 20%.

There are three possible outcomes from the planned analyses of mortality. Each row of Table 4 describes a particular scenario (pair of true mortality rates). The last 3 columns in each row show the percentage of simulations which exhibited each of the three possible outcomes.

1. If the observed death rates in the two randomized treatment arms are very different as the study progresses, the criteria for considering an early halt to the trial could be met. The percentage of simulations where this occurred is shown in column 5 of Table 4.
2. If the criteria for early stopping are not met, there might still be a statistically significant difference in mortality rates at the final analysis. The percentage of simulations where this occurred is shown in column 6.
3. If the criteria for early stopping are not met, there might be no statistically significant difference in mortality rates at the final analysis. The percentage of simulations where this occurred is shown in column 7.

Table 4: Operating characteristics for proposed interim analysis of mortality, based on 5,000 replications of each scenario

Note that because of the two-sided testing only one set of simulations was used for each pair of death rates (for example, the row for 30% mortality in the control arm and 50% mortality in the granulocyte arm is derived from the same set of simulations as the row for 50% mortality in the control arm and 30% mortality in the granulocyte arm).

P(Death) in Arm 1	P(Death) in Arm 2	Estimated Type I Error Rate (declaring significant difference when no difference exists)	Estimated Power (declaring a significant difference when a difference exists)	% Halted Early	If not halted early	
					% Significant at End	% Non-significant at End
0.30	0.10	--	0.9422	86.70	7.52	5.78
	0.20	--	0.3146	26.82	4.64	68.54
	0.30	0.0418	--	3.86	0.32	95.82
	0.40	--	0.2670	23.54	3.16	73.30
	0.50	--	0.8048	75.90	4.58	19.52
0.40	0.20	--	0.8526	80.36	4.90	14.74
	0.30	--	0.2670	23.54	3.16	73.30
	0.40	0.0452	--	4.30	0.22	95.48
	0.50	--	0.2604	23.54	2.50	73.96
	0.60	--	0.8042	75.80	4.62	19.58
0.50	0.30	--	0.8048	75.90	4.58	19.52
	0.40	--	0.2604	23.54	2.50	73.96
	0.50	0.0530	--	4.92	0.38	94.70
	0.60	--	0.2582	23.68	2.14	74.18
	0.70	--	0.8150	76.32	5.18	18.50

9. References

1. Pannuti C, Gingrich R, Pfaller MA, Kao C, Wenzel RP. Nosocomial pneumonia in subjects having bone marrow transplant. Attributable mortality and risk factors. Cancer 1992; 69:2653-62.
2. Iwen PC, Reed EC, Armitage JO, et al. Nosocomial invasive aspergillosis in lymphoma subjects treated with bone marrow or peripheral stem cell transplants. Infect Control Hosp Epi 1993; 14:131-9.
3. Saugier-Veber P, Devergie A, Sulahian A, Ribaud P, Traore Fe. Epidemiology and diagnosis of invasive pulmonary aspergillosis in bone marrow transplant subjects: results of a 5 year retrospective study. Bone Marrow Transplant 1993; 12:121-4.
4. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in subjects with acute leukemia. Annals of Internal Medicine 1984; 100:345-51.
5. Herzig RH, Herzig GP, Graw RG, Jr., Bull MI, Ray KK. Successful granulocyte transfusion therapy for gram-negative septicemia. A prospectively randomized controlled study. New England Journal of Medicine 1977; 296:701-5.
6. Higby DJ, Yates JW, Henderson ES, Holland JF. Filtration leukapheresis for granulocyte transfusion therapy. Clinical and laboratory studies. New England Journal of Medicine 1975; 292:761-6.
7. Vogler WR, Winton EF. A controlled study of the efficacy of granulocyte transfusions in subjects with neutropenia. Am J Med 1977; 63:548-55.
8. Alavi JB, Root RK, Djerassi I, et al. A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. New England Journal of Medicine 1977; 296:706-11.
9. Graw RG, Jr., Herzig G, Perry S, Henderson ES. Normal granulocyte transfusion therapy: treatment of septicemia due to gram-negative bacteria. New England Journal of Medicine 1972; 287:367-71.
10. Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993; 81:1883-8.
11. Caspar CB, Seger RA, Burger J, Gmur J. Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood 1993; 81:2866-71.
12. Chatta GS, Price TH, Allen RC, Dale DC. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 1994; 84:2923-9.
13. Price TH, Chatta GS, Dale DC. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 1996; 88:335-40.
14. Allen RC, Stevens PR, Price TH, Chatta GS, Dale DC. In vivo effects of recombinant human granulocyte colony-stimulating factor on neutrophil oxidative functions in normal human volunteers. J Infect Dis 1997; 175:1184-92.
15. Liles WC, Huang JE, Llewellyn C, SenGupta D, Price TH, Dale DC. A comparative trial of G-CSF and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers. Transfusion 1997; 37:182-7.
16. Liles WC, Rodger E, Dale DC. Combined administration of granulocyte colony-stimulating factor (G-CSF) and dexamethasone for the mobilization of granulocytes in normal donors: optimization of dosing. Transfusion 2000; 40:642-4.
17. Dale D, Liles W, Llewellyn C, Rodger E, Bowden R, Price T. Neutrophil transfusions: Kinetics and functions of mobilized with granulocyte colony-stimulating factor (G-CSF) and dexamethasone. Transfusion 1998; 38:713-721.
18. Price TH, Bowden RA, Boeckh M, Bux J, Nelson K, Liles WC, Dale DC. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of subjects with infections in hematopoietic stem cell transplantation. Blood 2000; 95:3302-9.
19. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole vs. amphotericin B for primary therapy of invasive aspergillosis. NEJM 2002; 347:408-15. 20.

20. Hubel K, Carter RA, Liles WC et al. Granulocyte transfusion therapy for infection in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion 2002; 42:1414-21.
21. Adkins DR, Goodnough LT, Shenoy, S, et al. Effect of leukocyte compatibility on neutrophil increment after transfusions of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation. Blood 2000; 95:3605-12.
22. Nichols WG, Strauss R, Ambruso D et al. G-CSF-stimulated granulocyte transfusions from unrelated community donors for severe infections during neutropenia: a phase II multicenter trial of feasibility and efficacy. Blood 2003; 102 (11):978a.
23. Hester JP, Dignani MC. Anaissie EJ et al. Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed subjects with established infection. J Clin Apheresis 1995;10:188-193.
24. Adkins D, Spitzer G, Johnston M, et al. Transfusions of granulocyte-colony-stimulating factor-mobilized granulocyte components to allogeneic transplant recipients: Analysis of kinetics and factors determining posttransfusion neutrophil and platelet counts. Transfusion 1998;38:722-728.
25. Grigg A, Vecchi L, Bardy P, et al. G-CSF stimulated donor granulocyte collections for prophylaxis and therapy of neutropenic sepsis. Aust NZ J Med 1996;26:813-818.
26. Stroncek DF, Yau YY, Oblitas J, et al. Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone. Transfusion 2001;41:1037-1044.
27. Peters C, Minkov M, Matthes-Martin S, et al. Leukocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic subjects. Brit J Haematol 1999;106:689-696.
28. Stroncek DF, Clay ME, Petzold ML, et al. Treatment of normal individuals with granulocyte-colony-stimulating factor: Donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion 1996, 36:601-610.
29. Anderlini P, Przepiorka D, Seong D, et al. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion 1996;36:590-595.
30. Platzbecker U, Prange-Krex G, Bornhauser M, et al. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion 2001;41:184-9.
31. Stroncek D, Shawkert T, Follman D, et al. G-CSF-induced spleen size changes in peripheral blood progenitor cell donor. Transfusion 2003; 43:609-613.
32. Zelen M. The randomization and stratification of patients to clinical trials. J Chron Dis. 1974; 27:365-75.
33. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. The Annals of Statistics 1988;16:1141-54.
34. Marubini E , Valsecchi MG. Analysing Survival Data from Clinical Trials and Observational Studies. New York, NY: John Wiley & Sons 1995.
35. Hudgens MG, Satten GA, Longini IM Jr. Nonparametric maximum likelihood estimation for competing risks survival data subject to interval censoring and truncation. Biometrics. 2001 Mar;57(1):74-80
36. Brahm Segal, personal communication

APPENDIX A: Definitions of infection and suggested treatments

I. Definitions of Fungal Infections

Table 1: Proven invasive fungal infection (if any of the criteria apply)

	Molds*	Yeasts*	Agents of endemic fungal disease[§] In a host with an illness consistent with endemic mycosis:
Microscopic analysis: sterile material	Histopathologic, cytopathologic, or direct microscopic examination[†] of a specimen obtained by a needle aspiration or biopsy in which hyphae or melanized yeast-like forms are seen accompanied by evidence of associated tissue damage	Histopathologic, cytopathologic or direct microscopic examination[†] of a needle aspiration or biopsy specimen from a normally sterile site (other than mucous membranes) showing yeast cells e.g. *Cryptococcus* species indicated by encapsulated budding yeasts, *Candida* species showing pseudohyphae or true hyphae [‡]	Histopathologic or direct microscopic demonstration of appropriate morphologic forms with a truly distinctive appearance characteristic of dimorphic fungi, such as *Coccidioides* species spherules, *Blastomyces dermatitidis* thick-walled broad-based budding yeasts, *Paracoccidioides brasiliensis* multiple budding yeast cells, and, in the case of histoplasmosis, the presence of characteristic intracellular yeast forms in a phagocyte in a peripheral blood smear or in tissue macrophages.
Culture – sterile material	Recovery of a Mold or 'black yeast' by culture from a sample obtained by a sterile procedure from a normally sterile and clinically or radiologically abnormal site consistent with an infectious disease process, excluding BAL, cranial sinus cavity, and urine.	Recovery of a yeast by culture from a sample obtained by a sterile procedure (including a freshly placed (<24 hours ago) drain) from a normally sterile site showing a clinical or radiological abnormality consistent with an infectious disease process	Recovery in culture from a specimen obtained from the affected site
Culture – blood	Blood culture that yields a Mold**, e.g. *Fusarium* spp. in the context of a compatible infectious disease process	Blood culture that yields yeast (e.g. *Cryptococcus* species, *Candida* species), or yeast-like fungi (e.g. *Trichosporon* spp.)	Recovery in culture from a specimen obtained from blood

Serological analysis: CSF	Not applicable	**Disseminated cryptococcosis**
		    cryptococcal antigen in CSF
			Coccidioidomycosis
			    demonstration of coccidioidal antibody in CSF, or a 2-dilution rise measured in two consecutive blood samples tested concurrently in the setting of an ongoing infectious disease process.
			 Paracoccidioidomycosis
			    Demonstration in 2 consecutive serum samples of a precipitin band to paracoccidioidin concurrently in the setting of an ongoing infectious disease process

* if culture is available, append identification at genus or species level from the culture results.

**recovery of *Aspergillus* species from blood cultures invariably represents contamination.

[†] tissue and cells submitted for histopathologic or cytopathologic studies should be stained by Grocott-Gomori methenamine silver stain or by periodic acid Schiff stain to facilitate inspection of fungal structures. Whenever possible, wet mounts of specimens from foci related to invasive fungal infectious disease should be stained with a fluorescent dye (e.g., calcofluor or Blankophor ™)

[‡] *Candida*, *Trichosporon* and yeast-like *Geotrichum* species and *Blastoschizomyces capitatus* may also form pseudohyphae or true hyphae

[§] Endemic mycoses includes histoplasmosis, blastomycosis, coccidioidomycosis, paracoccidioidomycosis, sporotrichosis and infection due to *Penicillium marneffei*. Onset within 3 months after presentation defines a primary pulmonary infection.

Table 2 Criteria for defining probable or presumptive invasive fungal infection. A "probable" invasive fungal infection is one that does not meet the criteria for proven invasive fungal infection, but meets at least one host factor criterion, at least one clinical criterion, and at least one microbiologic criterion. A "presumptive" invasive fungal infection is one that does not meet the criteria for proven invasive fungal infection, meets at least one host factor criterion, and meets at least one clinical criterion, but does not meet the microbiologic criteria.

Host factors
Host factors are not synonymous with risk factors and are characteristics by which individuals predisposed to invasive fungal diseases can be recognized. They are intended primarily to apply to patients treated for malignant disease and to recipients of allogeneic hematopoietic stem cell and solid organ transplant. These host factors are also applicable to those receiving corticosteroids and other T-cell suppressants as well as those with primary immune deficiencies

1) Recent history of neutropenia ($< 0.5 \times 10^9$/L {<500 neutrophils/mm^3} for >10 days) temporally related to the onset of fungal disease. For presumptive infections only: If a subject has relapsed or refractory acute leukemia or MDS they must be neutropenic but can satisfy this host factor even if neutropenic for < 10 days.
2) Receipt of an allogeneic stem cell transplant
3) Prolonged use of corticosteroids (excluding patients with allergic bronchopulmonary aspergillosis) at an average minimum dose of 0.3 mg/kg/day prednisone equivalent for > 3 weeks
4) Treatment with other recognized T-cell immune suppressants such as cyclosporine, TNF-α blockers, specific monoclonal antibodies such as alemtuzumab, nucleoside analogues during the past 90 days
5) Inherited severe immunodeficiency (e.g., chronic granulomatous disease, severe combined immunodeficiency)

Clinical criteria*

Lower respiratory tract fungal disease	*Tracheobronchitis*	*Sinonasal infection*	*CNS infection*	*Disseminated candidiasis†*
The presence of one of the following "specific" imaging signs on CT: 1. Well defined nodule(s) with or without a halo sign 2. Wedge-shaped infiltrate 3. Air crescent sign 4. Cavity **OR** the presence of a new non-specific focal infiltrate **PLUS** at least one of the following: 1. Pleural rub 2. Pleural pain 3. Hemoptysis	Tracheobronchial ulceration, nodule, pseudomembrane, plaque or eschar seen on bronchoscopy	Imaging showing sinusitis **PLUS** at least one of the following: 1. Acute localized pain (including pain radiating to eye) 2. Nasal ulcer, black eschar 3. Extension from the paranasal sinus across bony barriers, including into the orbit	Focal lesions on imaging **OR** Meningeal enhancement on MRI or CT	At least one of the following: 1. Small, target-like abscesses (new nodular filling defects, bull's-eye lesions) in liver or spleen of a patient who has had candidemia within the previous 2 weeks 2. Progressive "cotton wool" exudates on ophthalmologic examination

* Must be consistent with the microbiological findings, if any, and must be temporally related to current episode.
† the presence of signs and symptoms consistent with sepsis syndrome indicates acute disseminated disease whereas their absence denotes chronic disseminated disease.

Table 2a continued

Microbiological Criteria	
Direct test - Cytology, direct microscopy or culture	**Mold** in sputum, BAL fluid, bronchial brush or sinus aspirate samples indicated by one of the following: the presence of fungal elements indicating a Mold **OR** recovery by culture of a Mold (e.g. *Aspergillus* spp., *Fusarium* spp., Zygomycetes, *Scedosporium* spp.)
Indirect tests (Detection of antigen orcell wall constituents) [††]	**Aspergillosis**: Galactomannan antigen detected in plasma, serum, BAL fluid or CSF.
	Mycosis other than cryptococcosis and zygomycoses Beta-D-glucan detected in serum

[††] These tests are primarily applicable for aspergillosis and candidiasis and do not detect *Cryptococcus* species or Zygomycetes (e.g. *Rhizopus* spp., *Mucor* spp. *Absidia* spp.)

Table 2b: Probable Endemic Mycoses: A "probable" endemic mycoses infection is one that does not meet the criteria for proven invasive fungal infection, but meets at least one host factor criterion and the following clinical criterion.

Host factors
• See table 2a for list of host factors.

Clinical criterion
• Clinical picture consistent with endemic mycosis and mycological evidence, such as a positive *Histoplasma* antigen test result from urine, blood or CSF.

II. Eligible Types of Invasive Bacterial Tissue Infections and Bacteremia

- Typhlitis (neutropenic enterocolitis), defined as clinical signs and symptoms compatible with disease and typical evidence of disease by imaging techniques
  - o Culture confirmation is not required

- Proven invasive bacterial tissue infection, defined as an infection meeting all of the following three criteria:
  - o Pure or predominant culture from sterile site biopsy (sterile site = site that would normally be sterile) **OR** bronchoalveolar lavage (BAL); **OR** a blood culture of an organism that is a plausible cause of the infection (for example, isolation of Streptococcus pneumoniae from blood in a subject with pneumonia), **AND**
  - o clinical signs and symptoms compatible with localized bacterial infection (e.g. sinusitis, pneumonia, intra-abdominal abscess, perirectal cellulitis/ecthyma/abscess, lesions with crepitation or blebs, multiple skin lesions with bacteremia); **AND**
  - o evidence compatible with disease by imaging techniques, if infection of the chest or sinuses.

- Presumptive invasive bacterial tissue infection, defined as an infection meeting the following two criteria:
  - o clinical signs and symptoms compatible with localized bacterial infection (e.g. sinusitis, pneumonia, intra-abdominal abscess, perirectal cellulitis/ecthyma/abscess, lesions with crepitation or blebs, multiple skin lesions with bacteremia); **AND**
  - o evidence compatible with disease by imaging techniques, if infection of the chest or sinuses.

- Bacteremia, defined as:
  - o Positive isolate from bacterial blood cultures indicative of serious infection (e.g. gram negative bacteremia or S. aureus bacteremia) [coagulase-negative staphylococcal bacteremias are excluded] **AND**
  - o At least one of the following 3 criteria:

    - Subject has, in the opinion of the attending physician, ongoing hemodynamic instability (for example, the need for pressors, fluid boluses, or other intervention), **OR**

    - Signs and symptoms have been unresponsive to appropriate clinical and antimicrobial management for more than 24 hours, **OR**

    - Persistent fever for 48 hours, and more than one positive culture from the same organism, in spite of appropriate antimicrobial therapy. The second positive culture must be from a sample obtained at least 20 hours after the sample for the initial culture was drawn. The most recent culture results available at the time eligibility is determined must be positive.

Table 3: Minimum requirements for bacterial infection to meet study qualifying criteria for the RING study (must have all criteria indicated with an 'X' in the corresponding row for that infection).

	Positive isolate from blood culture[1,]	Clinical signs and symptoms compatible with disease[2]	Evidence of disease by imaging techniques	Subject has ongoing hemodynamic instability in opinion of attending physician[3]	Signs/symptoms unresponsive to appropriate clinical and antimicrobial management for more than 24 hours	Fever has persisted for at least 48 hours, and at least 2 positive cultures in spite of appropriate antimicrobial therapy[4]
Typhlitis (neutropenic enterocolitis)		X	X			
Invasive tissue infection (infection of chest or sinuses)		X	X			
Invasive tissue infection (other than types listed above)		X				
Bacteremia, alone	X			X		
	X				X	
	X					X

[1] For bacteremia, the organism must be indicative of serious infection, for example gram negative bacteremia or S. aureus bacteremia. Coagulase-negative staphylococcal bacteremias are excluded.

[2] Examples of signs and symptoms compatible with localized bacterial infection include: sinusitis, pneumonia, intra-abdominal abscess, perirectal cellulitis/ecthyma/abscess, lesions with crepitation or blebs, multiple skin lesions with bacteremia

[3] For example, need for pressors, fluid boluses, or other intervention

[4] Second culture must be from sample obtained >20 hours after initial culture; most recent culture with results available at the time eligibility is determined must be positive for the same organism

III. Suggested therapy for specific infections

A. Invasive mold infections due to:
   1. Aspergillus species: voriconazole +/- caspofungin
   2. Zygomycetes (agents of "mucormycosis"): lipid formulation of amphotericin B (AmBisome or ABLC; 5mg/kg/day) is preferred first-line therapy. Posaconazole may be considered as salvage therapy.
   3. Fusarium species: voriconazole or lipid formulation of amphotericin B (AmBisome or ABLC; 5mg/kg/day)
   4. Scedosporium species: voriconazole

B. Candidemia or deep tissue invasive candidiasis: echinocandin (caspofungin, micafungin or anidulafungin), conventional amphotericin B ($\geq$ 0.6 mg/kg/day); lipid formation of amphotericin B (3 to 5 mg/kg/day). Removal of central venous catheter is advised.

APPENDIX B: Definitions of response to therapy

Response for ***tissue invasive bacterial/ fungal infections*** will be categorized as:

1. <u>Complete response</u> – survival to 42 days after randomization, plus
   A   Elimination of all signs and symptoms of infection by clinical, laboratory and radiographic parameters, using the original imaging technique or an appropriate alternative imaging technique
       AND
   B   conversion of any positive bacterial/fungal cultures for the study-qualifying infection to negative unless specimens cannot be obtained because an invasive procedure is contraindicated

2. <u>Partial response</u> – survival to 42 days after randomization, plus
   A   Clinically important improvement in disease, including a demonstrable improvement in radiological or other diagnostic imaging findings, but criteria for complete response are not satisfied

3. <u>Failure</u> – Any of the following:
   - death from any cause within 42 days after randomization
   - lack of improvement of infection at day 42 after randomization
   - progression of infection at day 42 after randomization

4. <u>Indeterminate</u> – insufficient information available to determine subject's response

Response ***for bacterial/fungal bloodstream infection*** will be categorized as:

1. <u>Complete response</u> – survival to 42 days after randomization, plus
   A   Elimination of all signs and symptoms attributable to infection by clinical and laboratory parameters
       AND
   B   By day 42 after randomization, conversion to negative of any positive bacterial/fungal cultures for the study-qualifying infection (i.e. negative for the organism for which the subject was enrolled; subjects with positive blood cultures for other organisms may still be coded as complete responders)

2. <u>Failure</u> – Failure to achieve complete response.

3. <u>Indeterminate</u> – insufficient information available to determine subject's response

APPENDIX C: CTC categories for expected adverse events in the setting of chemotherapy, HSC transplantation and/or various other marrow failures

Cardiovascular (General)
Edema
Hypertension
Hypotension

Constitutional
Rigors, chills
Weight gain associated with VOD

Dermatology/Skin
Hand-foot skin reaction
Pruritis
Rash/dermatitis associated with high-dose chemotherapy or BMT studies
Rash/dermatitis associated with GVHD for BMT studies

Gastrointestinal
Colitis
Dehydration
Diarrhea associated with GVHD for BMT studies
Dysphagia, esophagitis, odynophagia
Dysphagia-esophageal related to radiation
Dysphagia-pharyngeal related to radiation
Gastritis
Ileus
Pancreatitis
Stomatitis/pharyngitis for BMT studies
Typhlitis

Hemorrhage
Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia
Hematuria
Hemoptysis
Hematemesis
Melena/GI bleeding
Rectal bleeding/hematochezia
Vaginal bleeding
Epistaxis

Hepatic
Alkaline phosphatase elevation
Bilirubin elevation
Bililrubin elevation associated with GVHD for BMT studies
GGT elevation
SGOT (AST) elevation
SGPT (ALT) elevation

Infection/Febrile Neutropenia
Catheter-related infection
Febrile neutropenia
Infection with grade 3 or 4 neutropenia
Infection with unknown ANC
Infection without neutropenia

Metabolic/Laboratory
Acidosis
Alkalosis
Amylase elevation
Hypercalcemia
Hypercholesterolemia
Hyperglycemia
Hyperkalemia
Hypermagnesemia
Hypernatremia
Hypertriglyceridemia
Hyperuricemia
Hypocalcemia
Hypoglycemia
Hypokalemia
Hypomagnesemia
Hyponatremia
Hypophosphatemia
Lipase elevation

Musculoskeletal
Muscle weakness

Pain
Abdominal pain or cramping

Pulmonary
Hypoxia
Pleural effusion
Pneumonitis/pulmonary infiltrates
Voice changes/stridor/larynx

Renal/Genitourinary
Bladder spasms
Creatinine elevation
Dysuria
Renal failure
Urinary electrolyte wasting
Urinary frequency/urgency
Urinary retention

Sexual/Reproductive Function
Persistent amenorrhea

Syndromes (not included in previous category)
Tumor lysis syndrome

BMT Complex/Multicomponent Events
Graft versus host disease
Stem cell infusion complications
Veno-Occlusive Disease (VOD)

PROTOCOL SIGNATURE PAGE

I have read the foregoing protocol and agree that it contains all necessary details for carrying out this study. I will conduct the study in accordance with the design and specific provisions outlined herein; deviations from the protocol are acceptable only with a mutually agreed upon protocol amendment.

I will provide copies of the protocol and all pertinent information to all individuals for whom I am responsible who assist in the conduct of this study. I will discuss this material with them to ensure they are fully informed regarding the device and/or drug and the conduct of the study.

I will use only the informed consent form approved by the Data Coordinating Center and will fulfill all responsibilities for submitting pertinent information to the Institutional Review Board or Ethics Committee responsible for this study.

I also agree to report all information or data in accordance with the protocol and, in particular, I agree to report any serious adverse experiences as defined in Section 7 of this protocol.

I further agree that the NIH and the Transfusion Medicine/Hemostasis Clinical Trials Network Data Coordinating Center have access to any source documents from which case report form information may have been generated.

The below signed confirm herewith to have read and understood this trial protocol and/or amendment and appendices; furthermore, to accomplish this study in accordance with the protocol and Good Clinical Practice guidelines, as well as local regulations; and to accept respective revisions approved by authorized personnel of NIH and by competent authorities.

PRINTED OR TYPED NAME(S)　　　　SIGNATURE　　　　　　　　DATE

_____　　_____　　_____
Principal Investigator(s)

_____　　_____　　_____
Principal Investigator(s)